Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
Erika Bocanegra, Director of HTC Business Development and Community Engagement at Luskin Orthopaedic Institute for Children, Lifespan Orthopaedic HTC, shared CHES Foundation, Inc.‘s post on LinkedIn:
“When I first started in the bleeding disorders space 25 years ago, many of the treatment options available today were hard to imagine.
Fast forward to today, and we we’ve witnessed incredible advances, from non-factor therapies and extended half-life products to gene therapy and more personalized approaches to care.
It’s been inspiring to watch the field evolve and, more importantly, to see the positive impact these innovations have had on the lives of patients and families.
Excited to see what the future holds!”
CHES Foundation, Inc. shared a post on LinkedIn:
“HYMPAVZI is now approved for people with hemophilia A or B ages 12+ with inhibitors, as well as children ages 6–11 with or without inhibitors.
This milestone also makes HYMPAVZI the first subcutaneous non-factor therapy available for children with hemophilia B ages 6–11.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research
-
Jul 8, 2026, 19:25Luca Saba: Why Does the Same Patient Have Different Plaque in Different Arteries?
-
Jul 8, 2026, 19:25Luisa Weiss: Understanding the Molecular Differences Between Acute and Chronic Coronary Syndromes.
-
Jul 8, 2026, 19:11J. Meireles-Brandao: Role of Modifiable Cardiovascular Risk Factors in Dementia Development
-
Jul 8, 2026, 16:58Emmanuel J Favaloro։ Acquired von Willebrand Syndrome: Key Concepts for Clinical Practice
-
Jul 8, 2026, 16:47Arun V. J: Why Healthcare Professionals Need More Than Medical Training
-
Jul 8, 2026, 16:38Mona Alfaraj: What Does This HbA₂ Pattern Suggest?